30 closest matches · ranked by relevance
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
Superficial Siderosis
Primary: Number of Participants Who Show Stability, Improvement or Decline in Self Reported Hearing — 13; 18; 0 Participants
Iron Overload · Excessive Body Iron Burden
Primary: Hepatic Iron Content in the Liver Using Liver Biopsy — 19.8 mcg
Iron Overload Due to Repeated Red Blood Cell Transfusions
Primary: The Percentage of Patients in Each Treatment Group Who Experience Post-dose Increases in Liver Enzyme Levels That Are Considered a Safety Concern. — 0; 0; 0; 0…
Siderosis · Neurological Disorder · Rare Diseases
Primary: Hearing Evaluation - Pure Tone Audiometry — 57.3 decibel hearing level
Healthy
Primary: Rate of Iron Excretion. — 1.07; 1.69; 1.08 milligrams per day — p=< 0.05
Pancreatic Cancer
Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
Iron Overload
Primary: Per Subject Evaluable DICOM Data Sets From Liver MRI — 21 Participants
Chronic Anemia · Transfusional Hemosiderosis
Primary: Absolute Change From Baseline in Liver Iron Concentration (LIC) to Year 1 — -10.9 mg Fe/g dw
Impaired Renal Function
Primary: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 — 445892.7; 932688.3; 1531185.8; 1261081.6 ng*hr/ml
Sickle Cell Disease · Iron Overload · Hemolytic Anemia
Primary: The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment — 30; 17; 30; 8 participants
Restless Legs
Primary: Duration Off Treatment — 6; 3; 2; 0 participants
End-Stage Renal Disease (ESRD)
Primary: Percent of Subjects Whose Hemoglobin (Hgb) Decreases by a Total of 1.0 Grams/ Deciliter (g/dL) (or More) From Baseline on Each of Two Successive Measurements. — 5; 6; 5…
Iron Deficiency Anaemia · Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 1.22; 1.14 g/dL
Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths as a Measure of Safety and Tolerability — 25; 3; 0 Participants
Thalassemia Major With Severe Transfusional Iron Overload
Primary: Number of Participants With Improvement in Liver Iron Concentration — 3 Participants
Sickle Cell Disease
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 17.56; 32.95 μg/mL
Fetal Growth Retardation
Primary: Number of Participants for Which Intervillous Placental Blood is Detected — 3 Participants
Iron Deficiency Anemia
Primary: Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize — 2 weeks
Cardiac Iron Overload
Primary: Change in Cardiac Iron Content From Baseline to Month 12 — 1.09 ratio
Cystic Fibrosis · Anemia, Iron-Deficiency
Primary: Change From Baseline in Hemoglobin Concentration (gm/dl) — 0.12; 0.09 gm/dl — p=0.81
Liver Iron Overload
Primary: The Relative Change From Baseline in Liver Iron Content (LIC) After Prolonged Use of Deferasirox — -21.9; -23.1 Percent change
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only) — 7.8 10^9 Neutrophils per Liter
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 2.49; 2.49 g/dL
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
Erythropoietic Protoporphyria · EPP · X-linked Protoporphyria
Primary: Change in Erythrocyte Protoporphyrin Levels — 2314.6; 2240.4 µg/dL
Sickle Cell Disease
Primary: Number of Participants With Adverse Events After Start of ICL670 — 131; 49; 1; 2 participants
Thalassemia · Sickle Cell Disease · Diamond Blackfan Anemia
Primary: Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events — 0; 0; 1; 4 Participants
Beta-thalassemia · Iron Overload
Primary: Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2* — 9.92; 11.73; 1.77; 11.93 milliseconds (msec)